506 related articles for article (PubMed ID: 33704937)
21. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
22. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
[TBL] [Abstract][Full Text] [Related]
23. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
[TBL] [Abstract][Full Text] [Related]
24. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
25. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Miesner M; Haferlach C; Bacher U; Weiss T; Macijewski K; Kohlmann A; Klein HU; Dugas M; Kern W; Schnittger S; Haferlach T
Blood; 2010 Oct; 116(15):2742-51. PubMed ID: 20581309
[TBL] [Abstract][Full Text] [Related]
26. 11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
Ibrahim S; Estey EH; Pierce S; Glassman A; Keating M; O'Brien S; Kantarjian HM; Albitar M
Am J Clin Pathol; 2000 Nov; 114(5):793-7. PubMed ID: 11068555
[TBL] [Abstract][Full Text] [Related]
27. [Next-generation sequencing and its application in acute myeloid leukemia and myelodysplastic syndrome].
Gu SC; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1545-9. PubMed ID: 22169322
[TBL] [Abstract][Full Text] [Related]
28. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
30. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
32. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
33. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
34. Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML.
Janiszewska H; Bąk A; Skonieczka K; Jaśkowiec A; Kiełbiński M; Jachalska A; Czyżewska M; Jaźwiec B; Kuliszkiewicz-Janus M; Czyż J; Kuliczkowski K; Haus O
Leuk Res; 2018 Jul; 70():74-78. PubMed ID: 29902706
[TBL] [Abstract][Full Text] [Related]
35. Shallow whole-genome sequencing of bone marrow aspirates in myelodysplastic neoplasms: A retrospective comparison with cytogenetics.
Rengifo LY; Smits S; Boeckx N; Michaux L; Vandenberghe P; Dewaele B
Genes Chromosomes Cancer; 2023 Nov; 62(11):663-671. PubMed ID: 37293982
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
37. Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.
Vosberg S; Herold T; Hartmann L; Neumann M; Opatz S; Metzeler KH; Schneider S; Graf A; Krebs S; Blum H; Baldus CD; Hiddemann W; Spiekermann K; Bohlander SK; Mansmann U; Greif PA
Genes Chromosomes Cancer; 2016 Jul; 55(7):553-67. PubMed ID: 27015608
[TBL] [Abstract][Full Text] [Related]
38. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
Bacher U; Kohlmann A; Haferlach T
Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
[TBL] [Abstract][Full Text] [Related]
39. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
Smith SM; Le Beau MM; Huo D; Karrison T; Sobecks RM; Anastasi J; Vardiman JW; Rowley JD; Larson RA
Blood; 2003 Jul; 102(1):43-52. PubMed ID: 12623843
[TBL] [Abstract][Full Text] [Related]
40. Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.
Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Grönberg H; Rantalainen M
J Natl Cancer Inst; 2018 Oct; 110(10):1094-1101. PubMed ID: 29506270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
